Alan L. Barry concentrates his practice on the litigation of intellectual property matters before U.S. district courts and courts of appeals, the International Trade Commission (ITC), the American Arbitration Association and the U.S. Patent and Trademark Office. With more than 30 years of trial experience, Alan has litigated patent, trademark, trade secret and copyright cases in a wide variety of technical fields including, biotechnology (ANDA, pharmaceutical, medical device, and stem cell-related technologies), robotics, digital cameras and image processing technology, computer-controlled measuring devices, electrical distribution equipment, optoelectronics, food packaging, manufacturing equipment, medical equipment.
Registered to practice before the U.S. Patent and Trademark Office, Alan focuses on the trial of patent cases before the Federal District Courts and the Patent Trial and Appeal Board. He has jury tried to verdict patent cases in diverse technologies around the United States. Alan represents complainants and respondents in section 337 intellectual property infringement investigations brought before the ITC, including obtaining a judgment of non-infringement, invalidity, and no domestic industry against Apple.
Alan also counsels clients on intellectual property strategy, portfolio development, and transactional matters.
Prior to joining K&L Gates, Alan was a member of the Executive Committee and head of the Intellectual Property Litigation Group for one of the firm's predecessor firms.
- Selected to Super Lawyers Illinois list in IP Litigation, 2005-2019
- Listed in the Best Lawyers in America for Patent Law, 2013-2021
- Listed as an "IP Star" in Managing IP, 2020
- American Bar Association
- American Intellectual Property Law Association
- Barristers of the Patent Law (Patent Jury Trial Lawyers Group)
- Chicago Bar Association (Former Chairman, Trademark/Copyright Sub-Committee)
- Intellectual Property Law Association of Chicago
Alan has lectured for the Chicago Bar Association, the Federal Bar Association, the Indiana Continuing Legal Education Forum, Chicago-Kent College of Law, the Chicagoland Pharmaceutical Discussion Group and the University of Southern California School of Law.